Form 4: Centessa Pharmaceuticals Executive Sells Shares Under 10b5-1 Plan

Centessa Pharmaceuticals' Chief People Officer, Karen M. Anderson, executed stock sales and option exercises under a pre-arranged 10b5-1 trading plan.

Summary

• Karen M. Anderson, Chief People Officer of Centessa Pharmaceuticals, engaged in multiple transactions involving the company's ordinary shares.
• On December 13, 2024, she exercised options to acquire 5,876 shares at $3.85 per share and then sold the same amount of shares at a weighted average price of $17.0139.
• On December 17, 2024, she exercised options to acquire 10,624 shares at $3.85 per share and then sold the same amount of shares at a weighted average price of $17.3227.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• Following these transactions, Ms. Anderson directly owns 71,525 ordinary shares and 43,510 share options.

Sentiment

Score: 6

Explanation: The document reflects routine executive stock transactions under a pre-arranged plan, which is neither particularly positive nor negative for the company's outlook.

Positives

• The transactions were part of a pre-planned trading strategy, which is a common practice for executives to avoid accusations of insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, although these were pre-planned.

Industry Context

This is a routine filing related to executive stock transactions, which is common in publicly traded companies. The use of a 10b5-1 plan is a standard practice to manage insider trading risks.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the pharmaceutical industry such as Pfizer, Moderna, and BioNTech.
• These plans allow executives to sell shares at predetermined times and prices, mitigating the risk of insider trading allegations.
• The reported prices of $17.0139 and $17.3227 per share are within the typical range for stock sales by executives in similar companies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as they involve the sale of shares by a company executive.

Key Dates

Keywords

Centessa Pharmaceuticals, insider trading, Form 4, stock options, Rule 10b5-1, executive compensation, share sales